Changeflow GovPing Healthcare & Life Sciences USPTO Patent Application: Modified Release Mino...
Routine Notice Added Draft

USPTO Patent Application: Modified Release Minoxidil Formulations

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO has published a patent application (US20260083737A1) detailing modified release minoxidil oral formulations and methods for treating hair loss. The application describes pharmaceutical compositions containing minoxidil or its salts, potentially with other active agents, and includes methods for their administration and related kits.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a USPTO patent application (US20260083737A1) filed on November 26, 2025, and published on March 26, 2026. It describes novel pharmaceutical formulations for oral administration of modified-release minoxidil, including compositions with additional active agents and methods for treating hair loss. The application also covers kits containing slow modified-release vehicles with oral minoxidil.

As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, it signals potential future intellectual property and market exclusivity for specific drug formulations related to hair loss treatment. Companies in the pharmaceutical sector, particularly those involved in dermatology or hair loss treatments, should monitor the progress of this and similar patent applications.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL

Application US20260083737A1 Kind: A1 Mar 26, 2026

Inventors

Reid WALDMAN

Abstract

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

CPC Classifications

A61K 31/506 A61K 9/0053 A61K 9/2013 A61K 9/2018 A61K 9/2054 A61K 9/28 A61P 17/14

Filing Date

2025-11-26

Application No.

19402798

View original document →

Named provisions

COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 26th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260083737A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Drug Labeling
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Drug Development Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!